Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christine Johnson

Physician Assistant, Medical Wichita, KS Physician Assistant

NPI 1245563006 CMS profile 10836965

818 N Emporia St, Ste 303, Wichita, KS 67214

Open in the dashboard

General payments

$4,387

105 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Johnson of Wichita, KS is reported in the CMS Open Payments database as having received $4,387 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,062 22
2024 General $378 6
2023 General $1,014 31
2022 General $462 22
2021 General $472 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Johnson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Christine Johnson were reported at $2,062. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Christine Johnson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $472 $156 $41–$563 $132
2022 $462 $185 $55–$649 $149
2023 $1,014 $199 $58–$717 $160
2024 $378 $206 $62–$740 $164
2025 $2,062 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,524 28 payments
  2. AstraZeneca Pharmaceuticals LP $473 13 payments
  3. Novartis Pharmaceuticals Corporation $459 25 payments
  4. Abbott Laboratories $121 3 payments
  5. Merck Sharp & Dohme Corporation $113 3 payments
  6. Actelion Pharmaceuticals US, Inc. $96 1 payment
  7. Abiomed $91 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $83 5 payments
  9. KCI USA, Inc $69 2 payments
  10. E.R. Squibb & Sons, L.L.C. $68 5 payments
  11. Other $289 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,837 95 payments
  2. Travel and Lodging $1,495 8 payments
  3. Education $54 2 payments
Products named General payments · program years 2021–2025
  1. LINQ II $658 7 payments
  2. LEQVIO Cardiology/Vascular Diseases $212 12 payments
  3. LEQVIO Cardiovascular $200 10 payments
  4. ENTRESTO $141 9 payments
  5. WAINUA $125 1 payment
  6. FARXIGA $114 7 payments
  7. VERQUVO $113 3 payments
  8. UPTRAVI $96 1 payment
  9. OPSUMIT $96 1 payment
  10. Impella $91 1 payment
  11. Other $891 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,602

Median for Physician Assistant: 241

Drug cost

$140,062

Median for Physician Assistant: $4,110

Branded share of claims

34%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 112 $79,830
Brilinta Ticagrelor Brand 53 $22,458
Farxiga Dapagliflozin Propanediol Brand 26 $19,793
Ezetimibe Generic 30 $1,795
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 81 $1,705
Clopidogrel Clopidogrel Bisulfate Brand 201 $1,468
Bumetanide Generic 43 $1,148
Flecainide Acetate Generic 19 $1,092
Amiodarone Hcl Generic 59 $1,090
Nitroglycerin Patch Nitroglycerin Brand 23 $1,034

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$21,235

Medicare's payments for the services billed

Medicare patients

206

Average age 77

Services billed

371

80 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 67%
Heart failure 51%
Arthritis 47%
Chronic kidney disease 44%
Diabetes 40%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $125
$125 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $48
$48 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $48
$48 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record